Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Q2 2020 Earnings Presentation
29 slides from Niagen Bioscience's earnings presentation, Aug 6, 2020
Slide 1: Earnings Conference Call Second Quarter 2020
ChromaDex Earnings Conference Call Second Quarter 2020 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer TRU NIAGEN Nasdaq: CDXC | August 6, 2020 1
Slide 2: TRU NIAGEN
TRU NIAGEN
Slide 3: Q2 2020 Takeaways
Q2 2020 Takeaways + Grew total net sales to $18.3 million in Q2 2020 (+38% YoY, +7% versus 1 2020) + Demonstrated continued progress building TRU NIAGEN into a global brand ‘+ TRU NIAGEN net sales of $11.7 milion in 2 2020 (+34% YoY). including a $1.6 millon purchase from Horizon Ventures + Continue
Slide 4: Build a Global Brand
Build a Global Brand ‘AUSTRALIA Matakana Healt i. Maren 2020 1) FRUNAGEN worn on heasn Om ho OH, Lened TO NAGEN a apt Ao 2020
Slide 5: Management Team
Management Team Rob Fried ~ Chief Executive Officer Board member since 2015, President, CEO & Director of ideation Acquison Corp. 2007-2008, Founder & CEO of Spiritips LLC 2007-2017 (acquired by Hallmark Cards inc. in 2012), and Academy Award and Emmy Award winning motion picture producer Frank Jaks
Slide 6: Scientific Advisory Board
Scientific Advisory Board
Slide 7: Scientific Update
Scientific Update
Slide 8: Science Continues to Expand
Science Continues to Expand + 42 human studies on nicotinamide riboside in various stages on clinicaltrials.gov) + One new clinical study on Niagen® since prior update : ‘+ Mclean Hospital, in collaboration with the National Institute on Aging (June 2020) + Study entitled “Effects of Nicotinamide Ri
Slide 9: Recent Peer-Reviewed Publications
Recent Peer-Reviewed Publications + Nature Scientific Reports Higashida eta, 2020 ~ ‘Nicotinamide rboside supplementation corrects deficits in oxytocin, sociability ‘and anxiety of C157 mutants ina mouse model of autism spectrum disorder.” June 2020 + Predinical study investigating the effects of Ni
Slide 10: Financial Highlights
Financial Highlights
Slide 11: Q2 2020 Net Sales Mix
Q2 2020 Net Sales Mix Q2.2019 Q2 2020 y 2 cer greets $11.1MM $15.3MM. AGEN ingredient wal =~ Se a a > TRU NIAGEN net sales were 77% of net sales in 02 2020 compared to 70% in Q2 20192), > NIAGEN-related net sales increased to 90% of net sales in Q2 2020 compared to 88% in ©2201) Successful transform
Slide 12: Q2 2020 Net Sales
Q2 2020 Net Sales Q2 2020 Net Sales Growth Rates (6 in millions) YoY % 00% (s022019) (vs. 012020) Agen moresent [IT 20 485% 12% creer [os sdearioatenet lor 20% 1% tinued strong ge Reference Standart (0 As tone Sst a Sern ey maid Cote
Slide 13: Year-to-Date 2020 Net Sales
Year-to-Date 2020 Net Sales YTD 2020 Net Sales (6 in millions) YoY % (st 2019) cnn ED | 20.00 229 rt racervonsen I «0 odo — amaetiter Bl 25 Total 440% rong growth in TRU NIAGEN, Ni Reference Standards & Servi (0 As tone Sst a Sern ey maid Cote
Slide 14: Q2 2020 vs Q1 2020 Key P&L Metrics
Q2 2020 vs Q1 2020 Key P&L Metrics "TRU NAGEN Businoss up Si ven bya STEMI Herzen | Net Sales $15,287 $14,345 purchase para csc by lover Watsons sales folowing nal ‘hementa ot Tu hagon Beauty last ua Up t800ps driven by product cos! savings natives and ovral Gross Profit 9,088 8311 ae on sunt cham o
Slide 15: Q2 2020 vs Q2 2019 Key P&L Metrics
Q2 2020 vs Q2 2019 Key P&L Metrics (in tmousanés) Net Sales $15,287 tt,t01 Gross Profit 6.254 Selling and Marketing 4,308, ‘TRU NAGEN business up 34% wth growth in gobal ecommerce, a 1 BUM purchase rom Herons mtmatonallaunehes Aus¥aa UK) and now laos (Persona Non) Up 3100p aren byproduct cost saving
Slide 16: Q2 2020 Operating Loss vs Q2 2019
Q2 2020 Operating Loss vs Q2 2019 a <p> <> es oo mt B i “ on oe onan erie = ay TRU NIAGEN
Slide 17: Adjusted EBITDA Summary
Adjusted EBITDA Summary ‘chromadex Corporation and Subsiaries Reconciiton of Non GAA? Financial Measures ‘nthousands) Trvee months ended TA Sep Dee Me I an 30, Sap 30) Dee NaS an ET ane ee Netioss, repre” $(8443) $ (8050) 5 (E05) $E2IB) SBI) S77) S72 S(88sH S92) SETH ‘Austins: reerest income) exsens
Slide 18: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights 16130120 | Key Drivers Ee 220 [ser Ler [onan [esr ‘cash Saas sieazr s1o760 steere | $ametz si2ece s18.900 ‘cash usedin operatons 0 gow he ‘osmess pus $5 ion eta rae teventon BS 8670 1071 ©9820 | FHBBE | 11280 12388 Investments lo supp growth Accounts Daven by mcof
Slide 19: Quarterly Cash Flow Highlights
Quarterly Cash Flow Highlights (ovnovsanas) FY 2018 62019 42 Fy 2019 | aa120 | ers0r20 | yt0 2020 NetLoes SO5816) 510357) 5(7755) (7.202) s8889)" | SRIaT) $1902) sa71) | $1819) Winking Captal 5089 a Senin tc) | gaya | gover arn 7em wim | gaan | wary ‘cash From (Used Fee) Investing Be cereus ng = egp
Slide 20: 2020 Financial Outlook
2020 Financial Outlook (or trosands) 2098 Actus 2019 Actua! Grown driven by U.S. e-Commerce busines, laurenesin new etematena markets (UK and ‘Anstala) and on new platters (Persona Nuiton. Net sates sussr sus201 ‘Gross Margin % inuid TAU NAGE Some i os on BM Sot an aaonal sup enon cot eave (asa % of
Slide 21: Cash Flow Break-even Framework
Cash Flow Break-even Framework ‘Quarterly P&L. Cee ramen + US, eCommerce marketing efiency * Watten'sinteratonal business + Acceleration n eoss borer launches Net Sates {-S190ilion Siccesi launch wih Nests 1 New business market oppodunites + Increased sales of TRU NIAGEN in e-Commerce Gross Marin ‘A
Slide 22: Appendix
Slide 23: NR has reached the significant milestone of registered human studies
NR has reached the significant milestone of 52 registered human studies Preclinical Research Clinical Health Outcomes 10 published clinical studies of NIAGEN® More than 100 preclinical peer feviewed studies have been published Investigating the science behing NIAGEN® New studies are now ‘examining c
Slide 24: Cellular Health Supports Intrinsic Capacity
Cellular Health Supports Intrinsic Capacity Intrinsic eapacity isthe composite ofa the mental and piyscal capacives that a ‘person can draw on and includes ther ‘diy to walk, thnk, see, hear. and ‘temember, (Source: WHO)
Slide 25: Most prominent human clinical research areas for Niagen
Most prominent human clinical research areas for Niagen® are vitality, locomotion, cognition, and sensory ieee Cowon CapactyPeromarce Autwerars Oeste ‘Smt Nae Fm Dagenerton Non Akole Fayre? Mc Fc eg Wego scope 25
Slide 26: 2018 — 2020 YTD Net Sales Summary
2018 — 2020 YTD Net Sales Summary Tem cone a a a ee ee P| AGEN Rete ee ea P| tt TRU NAGEN nA 250% GROMER tee SOML i 3G bE 3 F 3 3 #93 3 2 ay
Slide 27: Adjusted EBITDA 2018 vs 2019
Adjusted EBITDA 2018 vs 2019 ‘ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Financial Measures (in tnousands) Year ended ‘Yea over Vout Dee 57,2018 bes. 3,201 ‘change tons 8 reported” Saas) sams 1.109 ‘Austen Interest (income) pense n ur 708 Depreciation or 762 155 ‘amortzaton of
Slide 28: Nestle Supply and License Agreement
Nestle Supply and License Agreement Market Size — 2018 Est, Key Terms of the Agreement > Upfront payment: Shih Cash received in Qi 2019 > Amortized as revenue over sightly more than 4 years > Few major players > Nestlé exclusivity: > Nest Heat Exclusive rights in medical nutiton Somes tase 5 Co-excl
Slide 29: Contact Info
Contact Info Brianna Gerber Vice President of FP&A and Investor Relations T: +1.949.419.0288 ext. 127 BriannaG@chromadex.com www.chromadex.com Where to buy TRU NIAGEN® www.truniagen,com www.amazon.com